Publicaciones en colaboración con investigadores/as de University of Paris-Saclay (10)

2024

  1. Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)

    Alimentary Pharmacology and Therapeutics

2023

  1. The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors

    Cancer research, Vol. 83, Núm. 2, pp. 239-250

2022

  1. Bona fide atypical scrapie faithfully reproduced for the first time in a rodent model

    Acta Neuropathologica Communications, Vol. 10, Núm. 1

2021

  1. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

    The Lancet Oncology, Vol. 22, Núm. 4, pp. 463-475

  2. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis

    The Lancet Oncology, Vol. 22, Núm. 5, pp. 727-736

  3. Endoglin is an endothelial housekeeper against inflammation: Insight in ECFC-related permeability through LIMK/cofilin pathway

    International Journal of Molecular Sciences, Vol. 22, Núm. 16

  4. Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19

    New England Journal of Medicine, Vol. 385, Núm. 9, pp. 790-802

2020

  1. A missense in HSF2BP causing primary ovarian insufficiency affects meiotic recombination by its novel interactor c19orf57/brme1

    eLife, Vol. 9, pp. 1-93

2016

  1. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222